Sold as Cosela. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Trilaciclib Dihydrochloride (sold as Cosela), first approved Feb 12, 2021, with 0 new uses approved and 0 published complete response letters.
| Cosela | Part B | $21.5M | +6% | 808 |
| Cosela | Part D | $325K | +227% | 14 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Feb 12, 2021 | CoselaNDA 214200 ยท New molecular entity | Pharmacosmos | 3 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
